Low-dose nivolumab-induced responses in acute lymphoblastic leukaemia relapse after allogeneic haematopoietic stem cell transplantation

Low-dose nivolumab-induced responses in acute lymphoblastic leukaemia relapse after allogeneic... Ann Hematol (2017) 96:1569–1572 DOI 10.1007/s00277-017-3033-7 LETTER TO THE EDITOR Low-dose nivolumab-induced responses in acute lymphoblastic leukaemia relapse after allogeneic haematopoietic stem cell transplantation 1 1 1 Thomas S. Y. Chan & Joycelyn P. Y. Sim & Yok-Lam Kwong Received: 22 May 2017 /Accepted: 23 May 2017 /Published online: 1 June 2017 Springer-Verlag Berlin Heidelberg 2017 Dear Editor, Patient 1 was a 31-year-old woman presenting in 2013 with Relapse of acute leukaemia after allogeneic haematopoietic B cell ALL. Induction chemotherapy with hyper-CVAD (cy- stem cell transplantation (HSCT) has a dismal prognosis, de- clophosphamide, vincristine, doxorubicin, steroid, cytarabine, spite the use of chemotherapy, donor lymphocyte infusion methotrexate) resulted in first complete remission (CR1). She underwent a matched unrelated donor (MUD)-HSCT. Relapse (DLI) or second HSCT [1]. For relapses within 1 year post- HSCT, current strategies lead to survival in fewer than 10% of occurred 10 months later, and CR2 was achieved with MOAD cases [1, 2]. (methotrexate, vincristine, L-asparaginase, dexamethasone). Immunotherapy including the use of monoclonal antibod- She then received a second MUD-HSCT from a different do- ies inotuzumab ozogamicin (anti-CD22) and blinatumomab nor. Five months later, multiple subcutaneous nodules, renal (anti-CD19) [3], and chimeric antigen receptor T cells [4], http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Hematology Springer Journals

Low-dose nivolumab-induced responses in acute lymphoblastic leukaemia relapse after allogeneic haematopoietic stem cell transplantation

Loading next page...
 
/lp/springer_journal/low-dose-nivolumab-induced-responses-in-acute-lymphoblastic-leukaemia-zH00FYQJwQ
Publisher
Springer Berlin Heidelberg
Copyright
Copyright © 2017 by Springer-Verlag Berlin Heidelberg
Subject
Medicine & Public Health; Hematology; Oncology
ISSN
0939-5555
eISSN
1432-0584
D.O.I.
10.1007/s00277-017-3033-7
Publisher site
See Article on Publisher Site

Abstract

Ann Hematol (2017) 96:1569–1572 DOI 10.1007/s00277-017-3033-7 LETTER TO THE EDITOR Low-dose nivolumab-induced responses in acute lymphoblastic leukaemia relapse after allogeneic haematopoietic stem cell transplantation 1 1 1 Thomas S. Y. Chan & Joycelyn P. Y. Sim & Yok-Lam Kwong Received: 22 May 2017 /Accepted: 23 May 2017 /Published online: 1 June 2017 Springer-Verlag Berlin Heidelberg 2017 Dear Editor, Patient 1 was a 31-year-old woman presenting in 2013 with Relapse of acute leukaemia after allogeneic haematopoietic B cell ALL. Induction chemotherapy with hyper-CVAD (cy- stem cell transplantation (HSCT) has a dismal prognosis, de- clophosphamide, vincristine, doxorubicin, steroid, cytarabine, spite the use of chemotherapy, donor lymphocyte infusion methotrexate) resulted in first complete remission (CR1). She underwent a matched unrelated donor (MUD)-HSCT. Relapse (DLI) or second HSCT [1]. For relapses within 1 year post- HSCT, current strategies lead to survival in fewer than 10% of occurred 10 months later, and CR2 was achieved with MOAD cases [1, 2]. (methotrexate, vincristine, L-asparaginase, dexamethasone). Immunotherapy including the use of monoclonal antibod- She then received a second MUD-HSCT from a different do- ies inotuzumab ozogamicin (anti-CD22) and blinatumomab nor. Five months later, multiple subcutaneous nodules, renal (anti-CD19) [3], and chimeric antigen receptor T cells [4],

Journal

Annals of HematologySpringer Journals

Published: Jun 1, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off